NCT00461084 - Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma | Biotech Hunter

Enrollment

36

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Lymphoma

Interventions

DRUG

BIAXIN (CLARITHROMYCIN)

Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.

DRUG

Biaxin (clarithromycin)

Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York